每月补充高剂量维生素D对跌倒和非椎体骨折的影响:随机、双盲、安慰剂对照ViDA试验的次要和事后结局
ViDA试验在新西兰奥克兰单中心纳入50-84岁健康成人5110例,随机接受每月口服骨化醇100000IU或安慰剂,平均治疗3.4年。维生素D组跌倒校正HR 0.99(95%CI 0.92-1.07;p=0.82),非椎体骨折校正HR 1.19(95%CI 0.94-1.50;p=0.15),均无显著差异。
要点
- 每月骨化醇100000IU补充2.5-4.2年未预防健康成人跌倒。
- 非椎体骨折校正HR 1.19(95%CI 0.94-1.50),无显著差异。
- 作者认为需进一步研究每日维生素D剂量(联合或不联合钙)的效果。
核心结论
- 每月100000IU骨化醇补充2.5-4.2年未预防该健康、可走动成人人群的跌倒或骨折。
- 作者认为需进一步研究每日维生素D剂量(联合或不联合钙)的效果。
研究设计与样本
- 维生素D评估(ViDA)研究为随机、双盲、安慰剂对照试验,在新西兰奥克兰一个中心开展。
- 纳入50-84岁健康志愿者5110例,随机分配至骨化醇组(n=2558)或安慰剂组(n=2552)。
- 干预为初始口服200000IU(5.0 mg)骨化醇,随后每月100000IU(2.5 mg)骨化醇或等效安慰剂。
- 骨折分析纳入所有同意者并按意向性治疗分析;跌倒分析纳入返回至少一份问卷者。
- 随访至2015年7月31日,平均治疗时长3.4年(SD 0.4,范围2.5-4.2)。
主要发现
- 随访期间2638例报告跌倒,维生素D组2539例中1312例(52%),安慰剂组2517例中1326例(53%)。
- 跌倒的校正HR为0.99(95%CI 0.92-1.07;p=0.82),维生素D组对比安慰剂组,校正年龄、性别、族裔、近期跌倒史、体力活动和基线25(OH)D。
- 非椎体骨折报告于292例,维生素D组2558例中156例(6%),安慰剂组2550例中136例(5%)。
- 骨折的校正HR为1.19(95%CI 0.94-1.50;p=0.15),维生素D组对比安慰剂组。
- 试验期间123例(2%)死亡,维生素D组65例,安慰剂组58例,组间差异无统计学意义。
关键数值与推荐
- 基线平均25(OH)D浓度为63 nmol/L(SD 24),1534例(30%)低于50 nmol/L。
- 参与者平均年龄65.9岁(SD 8.3),2971例(58%)为男性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需进一步研究每日维生素D剂量(联合或不联合钙)的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adults with low concentrations of 25-hydroxyvitamin D (25[OH]D) in blood have an increased risk of falls and fractures, but randomised trials of vitamin D supplementation have had inconsistent results. We aimed to assess the effect of high-dose vitamin D supplementation on fractures and falls. METHODS: The Vitamin D Assessment (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy volunteers aged 50-84 years conducted at one centre in Auckland, New Zealand. Participants were randomly assigned to receive either an initial oral dose of 200 000 IU (5·0 mg) colecalciferol (vitamin D3) followed by monthly 100 000 IU (2·5 mg) colecalciferol or equivalent placebo dosing. The prespecified primary outcome was cardiovascular disease and secondary outcomes were respiratory illness and fractures. Here, we report secondary outcome data for fractures and post-hoc outcome data for falls. Cox proportional hazards models were used to estimate hazard ratios (HRs) for time to first fracture or time to first fall in individuals allocated vitamin D compared with placebo. The analysis of fractures included all participants who gave consent and was by intention-to-treat; the analysis of falls included all individuals who returned one or more questionnaires. This trial is registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12611000402943. FINDINGS: Between April 5, 2011, and Nov 6, 2012, 5110 participants were recruited and randomly assigned either colecalciferol (n=2558) or placebo (n=2552). Two participants allocated placebo withdrew consent after randomisation; thus, a total of 5108 individuals were included in the analysis of fractures. The mean age of participants was 65·9 years (SD 8·3) and 2971 (58%) were men. The mean concentration of 25(OH)D in blood was 63 nmol/L (SD 24) at baseline, with 1534 (30%) having 25(OH)D concentrations lower than 50 nmol/L. Follow-up was until July 31, 2015, with a mean treatment duration of 3·4 years (SD 0·4, range 2·5-4·2). During follow-up, 2638 participants reported having a fall, 1312 (52%) of 2539 in the vitamin D group compared with 1326 (53%) of 2517 in the placebo group. The HR for falls-adjusted for age, sex, ethnic origin, history of recent fall, physical activity, and baseline 25(OH)D-was 0·99 (95% CI 0·92-1·07; p=0·82) for vitamin D compared with placebo. Non-vertebral fractures were reported in 292 individuals, 156 (6%) of 2558 in the vitamin D group and 136 (5%) of 2550 in the placebo group. The adjusted HR for fractures was 1·19 (95% CI 0·94-1·50; p=0·15) for vitamin D compared with placebo. 123 (2%) people died during the trial, 65 assigned vitamin D and 58 allocated placebo; the difference between treatment groups was not significant. INTERPRETATION: High-dose bolus vitamin D supplementation of 100 000 IU colecalciferol monthly over 2·5-4·2 years did not prevent falls or fractures in this healthy, ambulatory, adult population. Further research is needed to ascertain the effects of daily vitamin D dosing, with or without calcium. FUNDING: Health Research Council of New Zealand and Accident Compensation Corporation of New Zealand.
引用
- Khaw KT, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial. Lancet Diabetes Endocrinol. 2017. PMID: 28461159. doi:10.1016/S2213-8587(17)30103-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。